Aktie A2N5Z6 ALTIMMUNE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Altimmune, Inc.

Aktien

A2N5Z6

US02155H2004

ALT

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 24.06.2024 		% 5 Tage % 1. Jan.
7,14 USD +11,39 % Intraday Chart für Altimmune, Inc. +20,61 % -36,53 %
23.06. Altimmune, Inc. präsentiert Daten der Phase-2-Studie MOMENTUM mit Pemvidutid bei Adipositas auf den 84. wissenschaftlichen Sitzungen der American Diabetes Association CI
12.06. Transcript : Altimmune, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit - ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N5Z6 Aktie
  4. Nachrichten Altimmune, Inc.
  5. Andere Sprachen